NH

Narayana Hrudayalaya Share Price

₹1,774.60 -16.1 (-0.9%)

18 May, 2025 19:52

SIP TrendupStart SIP in NH

Start SIP

Performance

  • Low
  • ₹1,763
  • High
  • ₹1,823
  • 52 Week Low
  • ₹1,080
  • 52 Week High
  • ₹1,872
  • Open Price₹1,805
  • Previous Close₹1,791
  • Volume258,767

Investment Returns

  • Over 1 Month -4.3%
  • Over 3 Month + 33.76%
  • Over 6 Month + 39.03%
  • Over 1 Year + 37.24%
SIP Lightning

Smart Investing Starts Here Start SIP with Narayana Hrudayalaya for Steady Growth!

Invest Now

Narayana Hrudayalaya Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.3
  • PEG Ratio
  • 29.9
  • Market Cap Cr
  • 36,266
  • P/B Ratio
  • 11.3
  • Average True Range
  • 58.79
  • EPS
  • 38.35
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 34.15
  • RSI
  • 54.51
  • MFI
  • 57.68

Narayana Hrudayalaya Financials

Narayana Hrudayalaya Technicals

EMA & SMA

Current Price
₹1,774.60
-16.1 (-0.9%)
pointer
  • stock-down_img
  • Bearish Moving Average 6
  • stock-up_img
  • Bullish Moving Average 10
  • 20 Day
  • ₹1,770.29
  • 50 Day
  • ₹1,687.66
  • 100 Day
  • ₹1,572.40
  • 200 Day
  • ₹1,448.71

Resistance and Support

1786.97 Pivot Speed
  • R3 1,871.23
  • R2 1,847.27
  • R1 1,810.93
  • S1 1,750.63
  • S2 1,726.67
  • S3 1,690.33

What's your outlook on Narayana Hrudayalaya?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Narayana Hrudayalaya Ltd. (Narayana Health) is a leading healthcare provider in India, offering affordable, high-quality medical care across various specialties, including cardiology, oncology, and neurology. It operates a network of multi-specialty hospitals across India and abroad.

Narayana Hrudayalaya has an operating revenue of Rs. 5,387.06 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 18% is great, ROE of 27% is exceptional. The company has a reasonable debt to equity of 41%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 5% and 29% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 91 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 25 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Narayana Hrudayalaya Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-23 Audited Results & Final Dividend
2025-02-14 Quarterly Results
2024-10-31 Quarterly Results
2024-08-02 Quarterly Results
2024-05-24 Audited Results & Final Dividend
Date Purpose Remarks
2024-08-02 FINAL Rs.4.00 per share(40%)Dividend
2023-07-07 FINAL Rs.2.50 per share(25%)Final Dividend
2022-08-23 FINAL Rs.1.00 per share(10%)Final Dividend
View More

Narayana Hrudayalaya F&O

Narayana Hrudayalaya Shareholding Pattern

63.85%
5.71%
1.7%
9.66%
0%
11.46%
7.62%

About Narayana Hrudayalaya

  • NSE Symbol
  • NH
  • BSE Symbol
  • 539551
  • Managing Director & Group CEO
  • Dr. Emmanuel Rupert
  • ISIN
  • INE410P01011

Similar Stocks to Narayana Hrudayalaya

Narayana Hrudayalaya FAQs

Narayana Hrudayalaya share price is ₹1,774 As on 18 May, 2025 | 19:38

The Market Cap of Narayana Hrudayalaya is ₹36265.9 Cr As on 18 May, 2025 | 19:38

The P/E ratio of Narayana Hrudayalaya is 46.3 As on 18 May, 2025 | 19:38

The PB ratio of Narayana Hrudayalaya is 11.3 As on 18 May, 2025 | 19:38

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23